FDA Approves Screws That Dissolve Inside Your Bones
Published Date: 6/5/2026
Rule
Summary
The FDA is officially classifying absorbable metallic bone fixation fasteners as Class II devices with special safety rules, making them easier to get to patients while keeping them safe and effective. This change helps doctors and patients by reducing red tape and encouraging new, helpful bone-fixing tech. The new rules took effect on June 5, 2026, but have been in place since March 29, 2023, so manufacturers should already be on board.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 2 costs, 0 mixed.
New Clinical, Testing, and Labeling Requirements
Manufacturers must meet special controls including clinical data showing full absorption, non-clinical performance testing (complete degradation profile, initial and degrading mechanical performance), biocompatibility, non-pyrogenicity, sterility and shelf-life testing. Labeling must include material composition, absorption byproducts, technical parameters, expiration/shelf life, instructions for revision surgery, time to complete absorption, and a summary of clinical data.
Absorbable Fixators Reclassified to Class II
The FDA has classified absorbable metallic bone fixation fasteners as Class II with special controls. The final order is effective June 5, 2026, and the classification has been applicable since March 29, 2023. FDA says this change reduces regulatory burdens and will enhance patients' access to these devices.
Creates Predicate Pathway for Future Devices
Because FDA used the De Novo process to classify this device, the absorbable metallic bone fixation fastener can serve as a predicate for future similar devices. Other device sponsors can use the less-burdensome 510(k) process instead of submitting a De Novo request or a premarket approval application for substantially equivalent devices.
510(k) Premarket Notification Still Required
FDA states that absorbable metallic bone fixation fasteners are subject to premarket notification under section 510(k). At this time, FDA has not determined that this device type should be exempt under section 510(m), so sponsors must submit a 510(k) before marketing.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-18333, Agency Information Collection Activities; Proposed Collection; Comment Request; Human Cells, Tissues, and Cellular and Tissue-Based Products
The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed reinstatement of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection associated with statutory and regulatory requirements that govern certain human cells, tissues, and cellular and tissue-based products (HCT/Ps).
2026-18299, Agency Information Collection Activities; Proposed Collection; Comment Request; Pregnancy Exposure Registry Enrollment Project: A Survey of Health Care Providers To Advance Pregnancy Safety Data Collection and Improve Health Communications
The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information and to allow 60 days for public comment in response to the notice. This notice solicits comments on a proposed study entitled "Pregnancy Exposure Registry Enrollment Project: A Survey of Health Care Providers to Advance Pregnancy Safety Data Collection and Improve Health Communications."
2026-18368, Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates; Guidance for Industry; Availability
The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a guidance for industry titled "Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates." This guidance describes the FDA's regulatory and enforcement priorities regarding the compounding of certain starter parenteral nutrition drug products for neonates by outsourcing facilities and by State-licensed pharmacies and Federal facilities that are not registered with FDA as outsourcing facilities. This guidance is being published for immediate implementation due to the expected market exit of the predominant source of certain starter parenteral nutrition drug products for neonates in the United States.
Previous / Next Documents
Previous: 2026-11301, Special Local Regulations; Marine Events Within the USCG East District
The Coast Guard is setting special rules for boats during the Blackbeard Festival on the Hampton River in Virginia from June 13-14, 2026. Boats must follow directions and stay out of certain areas during specific times to keep everyone safe. This means some waterways will be off-limits for short periods, so boaters should plan ahead and expect some delays.
Next: 2026-11304, Establishment of Class E Airspace; Wickenburg, AZ
Starting September 3, 2026, new Class E airspace will be set up around Wickenburg, Arizona to help pilots fly safely using instruments, especially when the weather isn’t great. This change mainly affects pilots and air traffic controllers by improving flight rules and procedures in the area. No extra costs for the public, just smoother and safer skies!